RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Champions Oncology - Stock

Champions Oncology Net Income 2024

Champions Oncology Net Income

-8.73 M USD

Ticker

CSBR

ISIN

US15870P3073

WKN

A14X6S

In 2024, Champions Oncology's profit amounted to -8.73 M USD, a 63.54% increase from the -5.34 M USD profit recorded in the previous year.

The Champions Oncology Net Income history

YEARNET INCOME (undefined USD)
2030e-
2029e-
2028e-
2027e-
2026e-
2025e-4,713.01
2025e-
2024e-8,732.93
2023-5,340
2022550
2021360
2020-1,980
2019130
2018-1,480
2017-6,880
2016-10,450
2015-13,140
2014-7,410
2013-6,330
2012-8,660
2011-3,800
2010-2,920
2009-2,240
2008-410
2007-170
2006-300
2005-250
2004-240

Champions Oncology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Champions Oncology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Champions Oncology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Champions Oncology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Champions Oncology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Champions Oncology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Champions Oncology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Champions Oncology’s growth potential.

Champions Oncology Revenue, Profit, and EBIT History

DateChampions Oncology RevenueChampions Oncology EBITChampions Oncology Net Income
2030e133.57 M undefined0 undefined0 undefined
2029e113.19 M undefined14.15 M undefined0 undefined
2028e95.93 M undefined9.59 M undefined0 undefined
2027e81.64 M undefined6.12 M undefined0 undefined
2026e70.99 M undefined1.78 M undefined0 undefined
2025e54.75 M undefined-5.79 M undefined-4.71 M undefined
2025e70.17 M undefined3.16 M undefined0 undefined
2024e49.82 M undefined-9.69 M undefined-8.73 M undefined
202353.87 M undefined-4.45 M undefined-5.34 M undefined
202249.11 M undefined610,000 undefined550,000 undefined
202141.04 M undefined370,000 undefined360,000 undefined
202032.12 M undefined-1.46 M undefined-1.98 M undefined
201927.07 M undefined270,000 undefined130,000 undefined
201820.24 M undefined-1.35 M undefined-1.48 M undefined
201715.41 M undefined-6.81 M undefined-6.88 M undefined
201611.18 M undefined-10.32 M undefined-10.45 M undefined
20158.86 M undefined-13.24 M undefined-13.14 M undefined
201411.55 M undefined-6.26 M undefined-7.41 M undefined
20138.32 M undefined-6.22 M undefined-6.33 M undefined
20127.15 M undefined-9.07 M undefined-8.66 M undefined
20116.88 M undefined-5.24 M undefined-3.8 M undefined
20104.89 M undefined-2.93 M undefined-2.92 M undefined
20093.71 M undefined-2.05 M undefined-2.24 M undefined
20081.4 M undefined-440,000 undefined-410,000 undefined
20070 undefined-170,000 undefined-170,000 undefined
20060 undefined-140,000 undefined-300,000 undefined
20050 undefined-110,000 undefined-250,000 undefined
20042 M undefined-220,000 undefined-240,000 undefined

Champions Oncology stock margins

The Champions Oncology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Champions Oncology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Champions Oncology.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Champions Oncology's sales revenue. A higher gross margin percentage indicates that the Champions Oncology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Champions Oncology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Champions Oncology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Champions Oncology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Champions Oncology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Champions Oncology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Champions Oncology Margin History

Champions Oncology Gross marginChampions Oncology Profit marginChampions Oncology EBIT marginChampions Oncology Profit margin
2030e45.18 %0 %0 %
2029e45.18 %12.5 %0 %
2028e45.18 %10 %0 %
2027e45.18 %7.5 %0 %
2026e45.18 %2.5 %0 %
2025e45.18 %-10.57 %-8.61 %
2025e45.18 %4.5 %0 %
2024e45.18 %-19.45 %-17.53 %
202345.18 %-8.26 %-9.91 %
202251.88 %1.24 %1.12 %
202147.73 %0.9 %0.88 %
202047.45 %-4.55 %-6.16 %
201947.28 %1 %0.48 %
201847.88 %-6.67 %-7.31 %
201737.05 %-44.19 %-44.65 %
201622.36 %-92.31 %-93.47 %
201513.88 %-149.44 %-148.31 %
201468.83 %-54.2 %-64.16 %
201336.06 %-74.76 %-76.08 %
201231.47 %-126.85 %-121.12 %
201148.98 %-76.16 %-55.23 %
201060.94 %-59.92 %-59.71 %
200948.52 %-55.26 %-60.38 %
200865 %-31.43 %-29.29 %
200745.18 %0 %0 %
200645.18 %0 %0 %
200545.18 %0 %0 %
200437.5 %-11 %-12 %

Champions Oncology Aktienanalyse

What does Champions Oncology do?

Champions Oncology Inc is an American company specialized in the development of personalized cancer therapies. It was founded in 2009 by Dr. Ronnie Morris and Joel Ackerman and is headquartered in Hackensack, New Jersey. The history of Champions Oncology began with Dr. Morris' previous work on the development of personalized cancer therapies. He wanted to improve the conventional, often ineffective method of chemotherapy by directly extracting and analyzing tumor cells from patients. Based on these analyses, a therapy tailored to each patient should then be developed. The idea of personalized cancer therapies was born and subsequently led to the founding of Champions Oncology. The business model of Champions Oncology consists of offering personalized solutions for the treatment of cancer to patients, doctors, and pharmaceutical companies. The company has three main divisions: patient services, translational services, and preclinical services. In the patient services division, Champions Oncology offers cancer patients the opportunity to receive personalized cancer therapies. For this purpose, a tumor sample is directly taken from the patient, analyzed, and a therapy tailored to the patient is developed based on the analysis. Patients can thus receive a treatment specifically tailored to them, potentially increasing their chances of recovery. The translational services division of Champions Oncology is focused on supporting pharmaceutical companies in the development of personalized anti-cancer drugs. For this purpose, Champions Oncology offers its platform, which allows tumor cells from patients to be cultured in a controlled environment and tested for their effectiveness against specific types of cancer. This way, pharmaceutical companies can test potential new drugs without having to conduct expensive and time-consuming clinical trials. The preclinical services division of Champions Oncology offers pharmaceutical companies preclinical studies on cancer therapies that are specifically tailored to their needs. For this purpose, the company has a broad portfolio of tumor models for various types of cancer that can be used for the development and validation of new therapies. Champions Oncology offers several products and services, all focused on the development of personalized cancer therapies. These include: - TumorGraft: This is a platform for the cultivation of tumor cells directly isolated from patient samples. The platform allows for testing the effectiveness of cancer therapies directly on a patient sample. - TumorImmune: This platform combines the TumorGraft technology with specific immune modulators to measure the interaction between the patient's immune system and the tumor. The platform aims to help identify therapeutic targets for new cancer treatments. - TumorEscape: This platform allows for the analysis of tumor cells' resistance to chemotherapy and other cancer treatments. This can help identify new targets for cancer treatment and improve the effectiveness of existing therapies. Overall, Champions Oncology is an innovative and promising company specializing in the development of personalized cancer therapies. With its unique platform technology and tailored services, it is well-positioned to meet the growing demand for personalized cancer therapies. Champions Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Champions Oncology's Profit Margins

The profit margins of Champions Oncology represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Champions Oncology's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Champions Oncology's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Champions Oncology's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Champions Oncology’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Champions Oncology Stock

How much profit has Champions Oncology made this year?

Champions Oncology has made -8.73 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 63.54% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Champions Oncology publish its earnings?

Champions Oncology publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Champions Oncology?

The profits of Champions Oncology are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Champions Oncology?

You can learn more about the earnings of Champions Oncology by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Champions Oncology pay?

Over the past 12 months, Champions Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Champions Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Champions Oncology?

The current dividend yield of Champions Oncology is .

When does Champions Oncology pay dividends?

Champions Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Champions Oncology?

Champions Oncology paid dividends every year for the past 0 years.

What is the dividend of Champions Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Champions Oncology located?

Champions Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Champions Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Champions Oncology from 6/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Champions Oncology pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Champions Oncology in the year 2023?

In the year 2023, Champions Oncology distributed 0 USD as dividends.

In which currency does Champions Oncology pay out the dividend?

The dividends of Champions Oncology are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Champions Oncology stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Champions Oncology

Our stock analysis for Champions Oncology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Champions Oncology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.